Johnson & Johnson (JNJ)
Here is What to Know Beyond Why Johnson & Johnson (JNJ) is a Trending Stock
Zacks.com users have recently been watching Johnson & Johnson (JNJ) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Why Johnson & Johnson Stock Still Has Room To Run
On July 16, Johnson & Johnson did what I've been waiting for, namely, its revenue and EPS beat Wall Street analysts' expectations by a wide margin. The 42.7% year-over-year decline in sales of its "outdated" superstar Stelara was more than offset by the strong performance of its oncology franchise. Sales of Erleada, which is becoming the "gold standard" in prostate cancer treatment, reached $908 million, up 17.8% quarter-over-quarter.
J&J Expects Better Top-Line Growth in 2H: Can It Achieve the Goal?
JNJ lifts 2025 sales and EPS outlook on strong Q2 results, with new drug launches and MedTech gains fueling momentum.
JNJ or AZN: Which Pharma Giant is a Better Buy Post Q2 Results?
JNJ edges out AZN following Q2 results with raised guidance, stronger estimate revisions and a more attractive valuation.
3 Top Dividend Kings I'm Planning on Buying
Finding dividend stocks that are reliable and have the balance sheet stability and cash flow profile to continue to grow their distributions over the long-term is what many investors are after.
US FDA says J&J's Ethicon issues correction related to surgical stapler
The U.S. drug regulator said on Friday Ethicon Endo-Surgery, a unit of Johnson & Johnson , issued a correction for certain lots of a part related to its surgical stapler and classified the action as "most serious".
Why Johnson & Johnson (JNJ) is a Top Momentum Stock for the Long-Term
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
4 Major Stocks Raise 2025 Guidance, Analyst Targets Rise
A wave of upgraded guidance from major U.S. companies is reshaping the outlook for the rest of 2025, and analysts are responding in kind. Strong Q2 earnings results have prompted several high-profile firms to lift their full-year forecasts, triggering a flurry of price target hikes across Wall Street.
Johnson & Johnson Stock Could Be Waking Up
Johnson & Johnson's stock appears undervalued, as sluggish revenue growth and margin contraction are offset by raised full-year guidance and a rebounding outlook. Both Innovative Medicine and MedTech segments show promising pipeline developments, with MedTech's growth and robotics ambitions offering future upside. Despite a dip in free cash flow, J&J's dividend remains attractive, with a solid 3.18% yield and a 62-year growth streak, supporting shareholder returns.
JNJ Seeks FDA Approval for Oral Psoriasis Drug Icotrokinra
Johnson & Johnson eyes FDA nod to icotrokinra after phase III studies show strong skin clearance and safety in plaque psoriasis.
Is Trending Stock Johnson & Johnson (JNJ) a Buy Now?
Recently, Zacks.com users have been paying close attention to Johnson & Johnson (JNJ). This makes it worthwhile to examine what the stock has in store.
Build Stability and Income With 3 Overlooked Dividend Leaders
Dividend investing is one of the most popular strategies among retail investors seeking a combination of stability and passive income. A long-term buy-and-hold approach for stalwart dividend players like The Coca-Cola Co. NYSE: KO or Johnson & Johnson NYSE: JNJ rewards patience and a commitment to reinvesting payouts over time.
